On the 10th anniversary of The Scientist’s survey of life science academics, institutions are contending with tighter budgets and larger administrative staffs, while working to sustain and inspire their researchers.
On the 10th anniversary of The Scientist’s survey of life science academics, institutions are contending with tighter budgets and larger administrative staffs, while working to sustain and inspire their researchers.
To cope with a growing shortage of hearts, livers, and lungs suitable for transplant, some scientists are genetically engineering pigs, while others are growing organs in the lab.
More than simply helping haul out a cell’s garbage, ubiquitin, with its panoply of chain lengths and shapes, marks and regulates many unrelated cellular processes.
After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval.
What can a twentysomething naked mole-rat tell us about fighting pain, cancer, and aging?
What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.
Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.
Telomeres have been linked to numerous diseases over the years, but how exactly short telomeres cause diseases and how medicine can prevent telomere erosion are still up for debate.
A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.
The creation of H5N1 bird flu strains that are transmissible between mammals has thrown the scientific community into a heated debate about whether such research should be allowed and how it should be regulated.